Merck: Keytruda combo shows encouraging anti-tumor activity
(CercleFinance.com) - New data on Merck's Keytruda in combination with Eisai's Lenvima demonstrated "encouraging" anti-tumor activity, the drugmakers said on Friday.
This early data showed "promising" results in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma, the companies said.
The results will be presented at the annual meeting of the Society for Immunotherapy of Cancer, which is being held in Washington, D.C. on 9-11 November, Merck and Eisai said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This early data showed "promising" results in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma, the companies said.
The results will be presented at the annual meeting of the Society for Immunotherapy of Cancer, which is being held in Washington, D.C. on 9-11 November, Merck and Eisai said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.